We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Snibe Co.,Ltd.

Shenzhen New Industries Biomedical Engineering Co., Ltd. (Snibe) is a global leader in the IVD field, with 30 years o... read more Featured Products: More products

Download Mobile App




Snibe Diagnostic Displays Analyzers at MEDLAB Europe 2018

By LabMedica International staff writers
Posted on 04 Oct 2018
Shenzhen New Industries Biomedical Engineering Co., Ltd. More...
{(Snibe Co. Ltd.) Shenzhen, China} showcased its latest range of chemiluminescent immunoassay analyzers at MEDLAB Europe 2018 held in Barcelona, Spain, from October 2-4, 2018.

More than 150 exhibitors showcased the latest cutting edge technologies and recent developments in the medical laboratory industry at the second edition of the show. MEDLAB Europe 2018 welcomed more than 2,600 international visitors and delegates, offering international manufacturers a chance to network with over 1,000 medical dealers and distributors from Spain, Italy, France, Germany, Portugal and other countries.

Snibe is a bio-medical company specialized in clinical laboratory instruments and in vitro diagnostic reagents. The company manufactures a range of chemiluminescent immunoassay analyzers and clinical chemistry analyzers. It has achieved several milestones, such as developing China's first automated CLIA analyzer and dedicated kits in 2008 and launching the country’s first integrated system in 2012. Snibe is also the first CLIA manufacturer in China to receive FDA clearance in 2017.

Snibe offers chemiluminescent immunoassay analyzers under the MAGLUMI series and its clinical chemistry analyzers under the Biossays series. Currently, more than 3,000 hospitals in China are using the company’s MAGLUMI CLIA system. Snibe also offers the Biolumi 8000 Integrated Lab System that combines an electrolyte module, chemistry module and immunoassay module in a single platform.



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.